Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage
- Registration Number
- NCT01091896
- Lead Sponsor
- University of Sao Paulo
- Brief Summary
The purpose of this study is to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without bevacizumab injection.
- Detailed Description
Postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative diabetic retinopathy. Bevacizumab (Avastin) is a potent inhibitor of angiogenesis and has been shown to decrease retinal and iris neovascularization in proliferative diabetic retinopathy. We believe that preoperative bevacizumab injection could reduce postoperative vitreous hemorrhage by decreasing the amount of abnormal vessels and intraoperative injection could also reduce postoperative vitreous hemorrhage by inhibiting the vessel formation after surgery
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1
- patients undergoing first vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy
- follow-up period of less than 3 months
- not first vitrectomy
- abnormal blood coagulation
- uncontrolled hypertension
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2- bevacizumab before vitrectomy bevacizumab Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy 3- bevacizumab after vitrectomy bevacizumab Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
- Primary Outcome Measures
Name Time Method Recurrent vitreous hemorrhage incidence after vitrectomy 3 months
- Secondary Outcome Measures
Name Time Method Visual outcome 3 months
Trial Locations
- Locations (1)
Hospital das Clínicas de Ribeirão Preto - University of São Paulo
🇧🇷Ribeirão Preto, SP, Brazil